These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 25670355)

  • 1. The Cholesterol Lowering Atherosclerosis Study (CLAS): what it tells us about niacin/colestipol therapy.
    Hemphill LC
    J Clin Lipidol; 2015; 9(1):11-3. PubMed ID: 25670355
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of colestipol-niacin therapy on human femoral atherosclerosis.
    Blankenhorn DH; Azen SP; Crawford DW; Nessim SA; Sanmarco ME; Selzer RH; Shircore AM; Wickham EC
    Circulation; 1991 Feb; 83(2):438-47. PubMed ID: 1991366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
    Blankenhorn DH; Nessim SA; Johnson RL; Sanmarco ME; Azen SP; Cashin-Hemphill L
    JAMA; 1987 Jun; 257(23):3233-40. PubMed ID: 3295315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
    Cashin-Hemphill L; Mack WJ; Pogoda JM; Sanmarco ME; Azen SP; Blankenhorn DH
    JAMA; 1990 Dec; 264(23):3013-7. PubMed ID: 2243429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study.
    Zhao XQ; Phan BA; Davis J; Isquith D; Dowdy AA; Boltz S; Neradilek M; Monick EA; Brockenbrough A; Hus-Frechette EE; Albers JJ; Brown BG
    J Clin Lipidol; 2016; 10(5):1091-7. PubMed ID: 27678425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results.
    Blankenhorn DH; Johnson RL; Nessim SA; Azen SP; Sanmarco ME; Selzer RH
    Control Clin Trials; 1987 Dec; 8(4):356-87. PubMed ID: 3327654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
    Hodis HN
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of two lipid-lowering treatments on quantitative coronary angiographic endpoints.
    Mack WJ; Xiang M; Shircore AM; Selzer RH; Hodis HN; Azen SP
    Cardiovasc Drugs Ther; 2000 Aug; 14(4):411-8. PubMed ID: 10999648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colestipol-niacin therapy and coronary atherosclerosis.
    JAMA; 1987 Nov; 258(19):2694-6. PubMed ID: 3669238
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect.
    Blankenhorn DH; Selzer RH; Mack WJ; Crawford DW; Pogoda J; Lee PL; Shircore AM; Azen SP
    Circulation; 1992 Dec; 86(6):1701-9. PubMed ID: 1451241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial quantitative coronary angiography and coronary events.
    Mack WJ; Xiang M; Selzer RH; Hodis HN
    Am Heart J; 2000 Jun; 139(6):993-9. PubMed ID: 10827379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug therapy in children and adolescents with familial hypercholesterolemia.
    Stein EA
    Prog Clin Biol Res; 1988; 255():273-80. PubMed ID: 3340641
    [No Abstract]   [Full Text] [Related]  

  • 14. Probucol further lowers the serum cholesterol of colestipol-treated patients with hypercholesterolemia.
    Schonfeld G; Witztum J; Basich P
    Artery; 1982; 10(2):99-104. PubMed ID: 7092583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging.
    Jaffer FA
    J Am Coll Cardiol; 2009 Nov; 54(19):1795-6. PubMed ID: 19874993
    [No Abstract]   [Full Text] [Related]  

  • 18. [Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
    März W
    MMW Fortschr Med; 2005 Apr; 147(14):14. PubMed ID: 15887675
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapy: raising HDL cholesterol levels: a flight of Icarus?
    Rossi GP; Rizzoni D
    Nat Rev Endocrinol; 2010 May; 6(5):245-6. PubMed ID: 20414314
    [No Abstract]   [Full Text] [Related]  

  • 20. Lipid-lowering drugs.
    Med Lett Drugs Ther; 1985 Aug; 27(695):74-6. PubMed ID: 3860714
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.